PRESENTATION

Q3 2022 — Results presentation

Q3 2022PDF · 20 pages1.7 MB


-- 1 of 20 --

3rd Quarter 2022
Earnings Call
October 18, 2022

-- 2 of 20 --

Cautionary Note on Forward-looking Statements
This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial
performance, product development, market position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The viewer is cautioned not to rely on
these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties
materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as
interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product
research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the
impact of patent expirations; the ability of the company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally
or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability
claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of
purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government
agencies; the Company’s ability to satisfy the necessary conditions to consummate the separation of the Company’s Consumer Health business on a timely basis or at all; the Company’s ability to
successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the separation; the New Consumer Health Company’s ability to succeed as a standalone
publicly traded company; and risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures
implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the company’s ability to execute business
continuity plans, as a result of the COVID-19 pandemic. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form
10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson &
Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or
on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update
any forward-looking statement as a result of new information or future events or developments.
Cautionary Note on Non-GAAP Financial Measures
This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release
and the Investor Relations section of the Company’s website at www.investor.jnj.com/sales-earnings.cfm.
3

-- 3 of 20 --

Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA
discovered using MorphoSys AG antibody technology
Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL
CONSTA developed in collaboration with Alkermes, Inc.
Infectious Diseases
PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with
ViiV Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in
part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development
Authority (BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH)
at the U.S. Department of Health and Human Services (HHS)
Cardiovascular/
Metabolism/Other
INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG;
PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx
Oncology
IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in
collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S, BALVERSA licensed and discovered in collaboration with Astex
Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; cilta-cel licensed and developed in collaboration with Legend Biotech USA Inc. and Legend
Biotech Ireland Limited, niraparib licensed from TESARO, Inc., an oncology-focused business within GSK, lazertinib licensed from Yuhan Corporation, DuoBody platform licensed from Genmab A/S
relates to several bispecific antibody programs, ENHANZE platform licensed from Halozyme Therapeutics, Inc.
Pulmonary Hypertension UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan
Global Public Health
Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and
preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical
services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN
(grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health and Human
Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C.. The initial work on Ebola was conducted
which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center
(VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus
multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C.
Strategic Partnerships,
Collaborations & Licensing Arrangements
4
During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or
licensed from other companies. The following is an acknowledgement of those relationships:

-- 4 of 20 --

Enterprise Highlights
Sales Performance and Earnings Review
Capital Allocation and Guidance
Q&A
5
Agenda
1
2
3
4
Ashley McEvoy
Executive Vice President
Worldwide Chairman,
MedTech
Thibaut Mongon
Executive Vice President
Worldwide Chairman,
Consumer Health
Jennifer Taubert
Executive Vice President
Worldwide Chairman,
Pharmaceuticals
Joseph J. Wolk
Executive Vice President
Chief Financial Officer
Jessica Moore
Vice President
Investor Relations

-- 5 of 20 --

Regional Sales Results Q3 2022 Q3 2021
% CHANGE
Reported Operational1
U.S. $12.5 $12.0 4.1% 4.1%
Europe 5.5 5.6 (1.1) 14.5
Western Hemisphere
(ex U.S.) 1.6 1.5 4.1 9.1
Asia-Pacific, Africa 4.3 4.3 (0.9) 10.5
International 11.3 11.4 (0.3) 12.3
Worldwide (WW) $23.8 $23.3 1.9% 8.1%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
3rd Quarter 2022 Sales
Dollars in Billions
6

-- 6 of 20 --

(1.9)%; 5.8%1
Q3 2022 Q3 2021
$2.55 $2.60
3rd Quarter 2022 Financial Highlights
Dollars in Billions, except EPS
Reported %; Operational %1
7
Sales
Adjusted Earnings2 Adjusted EPS2
1.9%; 8.1%1
$23.8 $23.3
GAAP Earnings
21.6%
$4.5
$3.7
(2.7)%
Q3 2022 Q3 2021
GAAP EPS
22.6%
$1.68
$1.37
Q3 2022	Q3 2022 Q3 2021 Q3 2021	Q3 2022 Q3 2021
$6.8 $7.0
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website

-- 7 of 20 --

OTC
$1,519
Skin Health/Beauty
$1,126
Oral Care
$375
Baby Care
$375
Women's Health
$225
Wound Care/Other
$176
$3,795
(0.4)%, 4.7%
WW Sales $MM
■ Reported Growth ■ Operational Growth1
Consumer Health Highlights – 3rd Quarter 2022
Operational growth1 across all regions
8
Key Drivers of Operational Performance1,3
OTC3 • Growth driven by price actions and increased Cough/Cold/Flu and pediatric fever
incidences as well as category recovery partially offset by U.S. supply constraints
Skin
Health/
Beauty
• Growth driven by price actions, market growth, and increased OUS demand for
NEUTROGENA and AVEENO due to strong new OUS product introductions
Oral Care
• Decline driven by softer consumption in China, category deceleration in EMEA and
LATAM, and suspension of personal care products in Russia partially offset by price
actions in the U.S.
Baby Care • Growth driven by price actions, market growth and AVEENO Baby facial cream
relaunch in ASPAC partially offset by competitive pressures in the U.S
Women’s
Health
• Growth driven by continued strong performance in India, price actions, and lapping
prior year supply disruption due to flooding in EMEA
Wound
Care/Other
• Decline driven by timing of club sales in Canada, U.S. market declines and lapping
prior year strong COVID-19 related demand partially offset by price actions primarily
in the U.S.
Adjusted Operational Sales2,3: WW 4.8%, U.S. 2.3%, Int’l 6.7%
Reported3: WW (0.4)%, U.S. 2.1%, Int’l (2.3)%
Operational1,3: WW 4.7%, U.S. 2.1%, Int’l 6.7%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes; Note: Values may not add due to rounding
2.5%, 7.2%
(3.0)%, 7.9%
(3.9)%, (2.5)%
(4.3)%, 1.6%
(5.8)%, (0.7)%
0.1%, 5.0%
3

-- 8 of 20 --

Key Drivers of Operational Performance1,3
Immunology
• STELARA increase driven by market growth and strong share gains in both
Crohn’s Disease and Ulcerative Colitis partially offset by a net unfavorable prior
period adjustment
• Strength in TREMFYA due to share gains in both Psoriasis and Psoriatic Arthritis,
as well as market growth
• REMICADE decline due to biosimilar competition
Infectious
Diseases3
• Growth driven by the contribution of the COVID-19 Vaccine
• Partially offset by increased competition for PREZISTA/PREZCOBIX/REZOLSTA
and PREZISTA OUS LOE
Neuroscience3
• Paliperidone long-acting injectables growth due to strength of INVEGA
SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA driven by new patient
starts and persistency, as well as the launch of INVEGA HAFYERA
Oncology
• DARZALEX increase driven by share gains in all regions, continued strong market
growth and uptake of the subcutaneous formulation
• Continued strong global launch of ERLEADA
• IMBRUVICA maintains its market leadership position, but declined due to
competitive pressures globally
Cardiovascular/
Metabolism/
Other
(CVM/Other)3
• XARELTO increase due to volume growth and share gains
• INVOKANA/INVOKAMET decline due to continued share erosion
Pulmonary
Hypertension
(PH)
• Growth driven by strong demand and share gains from UPTRAVI and OPSUMIT
• Partially offset by COVID-19 related market constraints across the portfolio and
unfavorable patient mix in OPSUMIT
• Continued declines in Other Pulmonary Hypertension
Adjusted Operational Sales2,3: WW 9.2%, U.S. 3.2%, Int’l 16.8%
Immunology
$4,287
Infectious Diseases
$1,295
Neuroscience
$1,681
Oncology
$4,064
CVM/Other
$1,034
PH
$852	$13,214
2.6%, 9.0%
WW Sales $MM
■ Reported Growth ■ Operational Growth1
Pharmaceutical Highlights – 3rd Quarter 2022
9
Reported3: WW 2.6%, U.S. 3.0%, Int’l 2.0%
Operational1,3: WW 9.0%, U.S. 3.0%, Int’l 16.7%
(0.6)%, 1.4%
(1.9)%, 3.0%
10.9%, 20.0%
0.0%, 5.9%
(6.0)%, 3.8%
0.9%, 5.6%
Continued above-market performance primarily driven by Oncology and Immunology
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes; Note: Values may not add due to rounding
3
3
3

-- 9 of 20 --

Orthopaedics
$2,095
Surgery
$2,422
Vision
$1,206
Interventional
Solutions
$1,060
$6,782
2.1%, 8.1%
WW Sales $MM
■ Reported Growth ■ Operational Growth1
MedTech Highlights – 3rd Quarter 2022
Operational growth1 reflects procedure recovery and benefits from innovation & commercial execution
10
Reported: WW 2.1%, U.S. 7.7%, Int’l (2.9)%
Operational1: WW 8.1%, U.S. 7.7%, Int’l 8.5%
Key Drivers of Operational Performance1
Interventional
Solutions
• Double digit growth in all regions fueled by continued market recovery, new product performance
(OCTARAY, QDOT and VIZIGO) and commercial execution
Orthopaedics
• Hips: Growth (~ +9% U.S. / ~ +4% WW), reflects procedure recovery, continued strength from the
portfolio (ACTIS Stem, PINNACLE Dual Mobility, KINCISE & VELYS Hip Navigation) and momentum in
the U.S. Ambulatory Surgery Center channel partially offset by impacts of volume-based procurement in
China and timing of OUS tenders
• Trauma: Growth primarily driven by market recovery and uptake of new products (Advanced Nailing
Systems, VA Clavicle)
• Knees: Growth (~ +10% U.S. / ~ +5% WW), driven primarily by procedure recovery, strength of the
ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution partially offset by
impacts of volume-based procurement in China and timing of OUS tenders
• Spine, Sports & Other: Growth reflects procedure recovery and benefit from new products in Spine,
Sports, Shoulders and VELYS Digital Solutions, partially offset by competitive pressures in Spine
• Spine: WW: ~ +3%, U.S.: ~ -3%, OUS ~ +9%
Surgery
• Advanced:
• Endocutters: ~ +8% Driven primarily by market recovery and new products (ECHELON Staple Line
Reinforcement) aided by a reclass from General Surgery (~+200 bps) partially offset by competitive
pressures in the U.S.
• Biosurgery: ~ +7% Reflects market recovery, primarily in ASPAC, market expansion efforts and new
products (SURGIFLO, SURGICEL Powder and VISTASEAL) partially offset by strong U.S. market
demand in the prior year for infection prevention products
• Energy: ~ +9% Driven by new product penetration (ENSEAL X1 curved, HARMONIC 1100,
HD1000i) coupled with competitive supply challenges partially offset by competitive pressures
• General: Growth driven primarily by market recovery coupled with technology penetration (Barbed
Sutures, PLUS Sutures & Topical Skin Adhesives)
Vision
• Contact Lenses/Other: Growth driven by market recovery, price actions, commercial execution, and
new products (OASYS Multifocal, DEFINE FRESH) as well as benefit of stocking in the U.S. related to
new product launches (~ +120bps on WW growth)
• Surgical: Growth primarily driven by success of new products (TECNIS Eyhance and TECNIS Synergy)
mostly offset by global supply challenges, high prior year Refractive comparison and reduction in prior
quarter ASPAC stocking (~ -300 bps)
Adjusted Operational Sales2: WW 8.1%, U.S. 7.5%, Int’l 8.7%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding; The MedTech segment was previously referred to as the Medical Devices segment
10.8%, 17.7%
1.4%, 8.6%
0.1%, 4.7%
0.7%, 7.1%

-- 10 of 20 --

2022 2021 %
Increase
(Decrease)	Amount % to Sales Amount % to Sales
Sales to customers $23,791 100.0 $23,338 100.0 1.9
Cost of products sold 7,807 32.8 7,250 31.1 7.7
Gross Profit 15,984 67.2 16,088 68.9 (0.6)
Selling, marketing and administrative expenses 6,089 25.6 6,000 25.7 1.5
Research and development expense 3,597 15.1 3,422 14.7 5.1
In-process research and development - - 900 3.9
Interest (income) expense, net (99) (0.4) 7 0.0
Other (income) expense, net 493 2.1 1,850 7.9
Restructuring 82 0.3 60 0.2
Earnings before provision for taxes on income 5,822 24.5 3,849 16.5 51.3
Provision for taxes on income 1,364 5.8 182 0.8 649.5
Net Earnings $4,458 18.7 $3,667 15.7 21.6
-
Net earnings per share (Diluted) $1.68 $1.37 22.6
Average shares outstanding (Diluted) 2,661.3 2,674.9
Effective tax rate 23.4% 4.7%
.
Adjusted earnings before provision for taxes and net earnings1
Earnings before provision for taxes on income $8,073 33.9 $8,058 34.5 0.2
Net earnings $6,779 28.5 $6,968 29.9 (2.7)
Net earnings per share (Diluted) $2.55 $2.60 (1.9)
Effective tax rate 16.0% 13.5%
Condensed Consolidated Statement of Earnings
1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 11
3rd Quarter 2022
(Unaudited; Dollar and Shares in Millions Except Per Share Figures)

-- 11 of 20 --

2022 2021
Adjusted Income Before Tax by Segment1
3rd Quarter 2022
12
Pharmaceutical
MedTech
Consumer Health
Expenses Not Allocated to Segments
Q3 2022 Q3 2021
Pharmaceutical3 41.9% 43.8%
MedTech 25.5% 25.5%
Consumer Health3 24.3% 24.2%
Total 33.9% 34.5%
% to Sales
1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website
2 Estimated as of 10/18/2022
3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes
($0.1) ($0.2)
$8.1B
$5.7
$1.7
$0.9
$8.1B
$5.6
$1.7
$0.9
2

-- 12 of 20 --

Joseph J. Wolk
Executive Vice President,
Chief Financial Officer

-- 13 of 20 --

Capital Allocation Strategy
Capital Allocation
Organic growth business needs
Free cash flow1
Priorities are clear and remain unchanged
Competitive dividends
Share repurchases
HIGHER
PRIORITY
LOWER
PRIORITY
Investment in M&A
Dollars in Billions Q3 2022
Cash and Marketable
Securities $34
Debt ($32)
Net Cash $2
Free Cash Flow1,2 ~$13
Q3 2022:
$3.6B invested in R&D;
$10.8B year-to-date
$3.0B in dividends paid
to shareholders;
$8.7B year-to-date
Note: values may have been rounded
1 Non-GAAP measure; cash flow from operations less CAPEX
2 Estimated as of October 18, 2022. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings
3 Announced $5B share repurchase program on September 14, 2022 14
Note: values may have been rounded
$2.0B in share repurchases;
~40% of the program completed3

-- 14 of 20 --

Source: The New York Times; Bureau of Labor Statistics
As of September 13, 2022 15
U.S. Inflation Remains at Highest Levels
Since the 1980s

-- 15 of 20 --

1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items
2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses
3 Euro Average Rate: October 2022 = $1.04; Euro Spot Rate: October 2022 = $0.97 6 Excludes COVID-19 Vaccine
Note: Percentages may be rounded. 16
October July Comments
Adjusted Operational Sales1,2,6 6.7% - 7.2% 6.5% - 7.5% Tightening of range
Operational Sales2,6 $97.5B - $98.0B
6.7% - 7.2%
$97.3B - $98.3B
6.5% - 7.5% Reaffirming midpoint of 7.0%
Estimated Reported Sales3,6 $93.0B - $93.5B
1.8% - 2.3%
$93.3B - $94.3B
2.1% - 3.1% Incremental FX ($0.5B)
Adjusted Pre-Tax
Operating Margin4,5 ~50 bps decline ~Flat Lowering due to continued
impacts of inflation
Net Other Income4 $1.7 – $1.8 billion $1.4 - $1.5 billion Increasing based on
year-to-date trends
Net Interest (Income) /
Expense ($175) – ($200) million $0 Increasing income based on
year-to-date trends
Effective Tax Rate4 15.0% - 15.5% 15.0% - 15.5% Maintaining
Adjusted EPS (Operational)2,4 $10.70 - $10.75
9.2% - 9.7%
$10.65 - $10.75
8.7% - 9.7%
Tightening of range;
Increasing midpoint by $0.03
Adjusted EPS (Reported)3,4 $10.02 - $10.07
2.3% - 2.8%
$10.00 - $10.10
2.1% - 3.1%
Reaffirming midpoint of $10.05
despite incremental FX ($0.03)
2022 P&L Guidance
Reaffirming Adjusted Operational Sales and Reported Adjusted EPS midpoints; Increasing Adjusted Operational EPS
performance offsetting continued unfavorable currency impacts

-- 16 of 20 --

2023 Considerations
• Remain confident in our ability to
grow sales every year toward
our goal of $60B by 2025
• Stelara loss of exclusivity (LOE)
anticipated to occur in the
second half of 2023 in the U.S.
• Impact from new products and
commercial execution expected
to enhance our competitiveness
• Anticipating positive procedure
trends, but some continuing
market headwinds (supply and
staffing constraints, VBP)
• Continue to utilize strategic price
increases to offset inflationary
pressures; expect reduction in
supply chain disruptions
• Macroeconomic and geopolitical
environment remains dynamic
(freight, energy prices, supply)
• Expect some improvement in inflationary pressures in 2023, however higher costs of inventory manufactured in 2022 will
negatively impact 2023
• Further announcements related to Kenvue expected later this year or early 2023; remain on track to complete separation
mid-to-late 2023
• At this time, anticipate an unfavorable currency impact of ~$0.40 - $0.45 on adjusted earnings per share in 2023
Pharmaceutical MedTech Consumer Health
Enterprise and P&L
17

-- 17 of 20 --

Notable Announcements in 3rd Quarter 20221
Consumer Health
– Johnson & Johnson Appoints Larry Merlo as Non-Executive Chair Designate of Planned New Consumer Health Company
– Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company
MedTech
• Product Launches:
– Biosense Webster Launches the OCTARAY Mapping Catheter with TRUEref Technology
– Johnson & Johnson Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology
– Johnson & Johnson Vision Launches New Contact Lens Innovation to Help Meet the Needs of Digitally Intense Lifestyles: ACUVUE OASYS MAX 1-Day
– Biosense Webster Launches HELIOSTAR in Europe, the First Radiofrequency Balloon Ablation Catheter, Enabling Physicians to Perform More Efficient Cardiac Ablations2
Pharmaceutical
• Regulatory Decisions:
– STELARA (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
– European Commission Approves IMBRUVICA (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
– Janssen Marks First Approval Worldwide for TECVAYLI (teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma
– U.S. FDA Approves IMBRUVICA (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
• Data Release:
– Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT and Lazertinib Combination for Patients with Non -Small Cell Lung Cancer and EGFR Mutations
– Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
– TREMFYA (guselkumab) Demonstrates Higher Rates of Complete Skin Clearance with Earlier Treatment in Adults with Moderate to Severe Plaque Psoria sis in Phase 3b GUIDE Study
– Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and
Endoscopic Remission at Week 382
– STELARA (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis2
– Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual Meeting
Enterprise
– Johnson & Johnson Announces $5 Billion Share Repurchase Program
– Johnson & Johnson Opens State-of-the-Art Science and Technology Campus in San Francisco Bay Area
181 These developments and all other news releases are available on the company’s website at news releases or JNJ.com news releases, as well as www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and www.LTLManagementInformation.com
2 Subsequent to the Quarter

-- 18 of 20 --

Q&A
Jennifer Taubert
Executive Vice President
Worldwide Chairman,
Pharmaceuticals
Executive Vice President
Worldwide Chairman,
MedTech
Ashley McEvoy Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Thibaut Mongon
Executive Vice President
Worldwide Chairman,
Consumer Health

-- 19 of 20 --



-- 20 of 20 --